Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9

MLA

Tetsuo Ashizawa, et al. “Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9.” Molecular Therapy, vol. 26, Nov. 2018, pp. 2617–30. EBSCOhost, https://doi.org/10.1016/j.ymthe.2018.09.003.

APA

Tetsuo Ashizawa, Xiuming Guo, Naohiro Terada, Arjun Thapa, Guangbin Xia, Hui Li, Lei Hao, Yanlin Wang, Hongcai Wang, Katherine E. Santostefano, & John D. Cleary. (2018). Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9. Molecular Therapy, 26, 2617–2630. https://doi.org/10.1016/j.ymthe.2018.09.003

Chicago

Tetsuo Ashizawa, Xiuming Guo, Naohiro Terada, Arjun Thapa, Guangbin Xia, Hui Li, Lei Hao, et al. 2018. “Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9.” Molecular Therapy 26 (November): 2617–30. doi:10.1016/j.ymthe.2018.09.003.